Skip to main content

Table 2 Demographic and clinical data of the cases deceased due to thromboembolism

From: Maternal mortality following thromboembolism; incidences and prophylaxis strategies

variable

N (%)

Type of hospital

Educational

21 (77.8)

Private

5 (18.5)

Charity

1 (3.7)

BMIa

<  30

23 (85.2)

30–40

4 (14.8)

≥ 40

0

Blood Group

A+

11 (40.7)

O+

8 (29.6)

B+

5 (18.5)

AB+

2 (7.4)

O

1 (3.7)

A

0

B

0

AB

0

Delivery Type

NVDb

6 (22.2)

CSc

Emergency

7 (25.9)

Elective

14 (51.9)

Parity

≥3

10 (37)

< 3

17 (63)

Infant gender

Male

14 (51.9)

Female

13 (48.1)

1st min. Apgar Score

0

6 (22.2)

5

1 (3.7)

6

1 (3.7)

7

4 (14.8)

8

3 (11.1)

9

12 (44.4)

Death time

Morning shift

18 (66.7)

Evening shift

9 (33.3)

Delivery to death (days)

1

20 (74.1)

2

3 (11.1)

3

1 (3.7)

4

1 (3.7)

7

1 (3.7)

12

1 (3.7)

Blood transfusion

Yes

11 (40.7)

No

16 (59.3)

Heparin prescription

Yes

Single dose

6 (22.2)

multiple doses

5 (18.5)

No

16 (59.3)

Time of Heparin prescription

Before surgery

5 (18.5)

After surgery

1 (3.7)

Before & after surgery

5 (18.5)

None

16 (59.3)

Preterm labor

Yes

13 (48.1)

No

14 (51.9)

IUFDd

Yes

7 (25.9)

No

20 (74.1)

Postpartum hemorrhage

Yes

7 (25.9)

No

20 (74.1)

Prolonged labor

Yes

1 (3.7)

No

26 (96.3)

Instrumental delivery

Yes

2 (7.4)

No

25 (92.6)

Sepsis

Yes

3 (11.1)

No

24 (88.9)

Multiple pregnancy

Yes

3 (11.1)

No

24 (88.9)

IVF/ARTe

Yes

4 (14.8)

No

23 (85.2)

Antiphospholipid syndrome

Yes

1 (3.7)

No

26 (96.3)

Cardiac Disease

Yes

8 (29.6)

No

19 (70.4)

Hypothyroidism

Yes

1 (3.7)

No

26 (96.3)

Cancer

Yes

1 (3.7)

No

26 (96.3)

Diabetes

Yes

4 (14.8)

No

23 (85.2)

Rheumatoid disease

Yes

1 (3.7)

No

26 (96.3)

Hereditary thrombophilia

Yes

1 (3.7)

No

26 (96.3)

Preeclampsia

Yes

1 (3.7)

No

26 (96.3)

Chronic hypertension

Yes

3 (11.1)

No

24 (88.9)

Thromboembolism history

Yes

1 (3.7)

No

26 (96.3)

  1. abody mass index, bnormal vaginal delivery, ccesarean section, dintra uterine fetal demise, ein vitro fertilization/ assisted reproductive technology